EUVIMEDEUVIMED entdecken
Open Access

Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma

Marina Ninkov, Crystal L Schmerk, Manoosh Moradizadeh, Seema N Parvathy, Rene Figueredo, Jeremy P Burton, Michael S Silverman, Ricardo Fernandes, Saman Maleki Vareki, S M Mansour Haeryfar

Cancer Immunology, Immunotherapy · 2023-05 · 72 (5) · 1247-1260

DOI: 10.1007/s00262-022-03329-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.11.2022. Verfasst von Marina Ninkov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Mucosal-Associated Invariant T Cells, Kidney Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: London Regional Cancer Program, Canadian Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Strategies to modify the gut microbiome in cancer patients using fecal microbiota transplantation (FMT) have gained momentum as a therapeutic intervention. However, how FMT impacts innate-like, antimicrobial T lymphocytes is unclear. In this study, we assessed peripheral blood (PB) mucosa-associated invariant T (MAIT) cell frequencies and functions in patients with metastatic renal cell carcinoma (mRCC) before and seven days after they received FMT as part of a clinical trial. We found comparable MAIT cell frequencies in healthy controls and mRCC patients. In contrast, γδ T cells exhibited a numerical decline in mRCC, which was partially reversed by FMT. We also found a significant increase in the PB CD4+ MAIT cell compartment of mRCC patients with or without FMT. Paired sample analyses revealed CD69 upregulation on MAIT cells accompanied by decreased PD-1 levels post-FMT. These changes were unique to MAIT cells as non-MAIT T lymphocytes showed either no trend or a trend in the opposite direction. Importantly, FMT did not render MAIT cells exhausted as also judged by their stable expression of TIM-3, LAG-3, BTLA, CTLA-4, TIGIT and VISTA. These findings were corroborated in functional assays in which MAIT cells were stimulated with MR1 ligands or with a combination of IL-12 and IL-18 to produce inflammatory cytokines and granzyme B. Indeed, when stimulated ex vivo with IL-12 and IL-18, MAIT cells mounted a more rigorous TNF-α response post-FMT. In conclusion, FMT improves MAIT cell functions, which should serve patients well in subsequent microbial challenges in the face of cancer-elicited immunosuppression. Trial Registration: https://clinicaltrials.gov/ Identifier: NCT04163289 (registration date: November 14, 2019).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellMucosal-Associated Invariant T CellsKidney NeoplasmsHumansInterleukin-18Fecal Microbiota TransplantationInterleukin-12

Stichwörter der Autor:innen

CytokineFecal microbiota transplantationKidney cancerMAIT cellsMR1Renal cell carcinoma

Substanzen

Interleukin-18Interleukin-12

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Western University, 1151 Richmond Street, London, ON, N6A 5C1, Canada.
  • Department of Surgery, Division of General Surgery, Western University, London, ON, Canada.
  • Department of Medicine, Division of Infectious Diseases, Western University, London, ON, Canada.
  • Department of Oncology, Western University, London, ON, Canada.
  • Department of Surgery, Division of Urology, Western University, London, ON, Canada.
  • Lawson Health Research Institute, London, ON, Canada.

Förderung

  • London Regional Cancer Program
  • Canadian Cancer Society

Zitieren

APA

Ninkov, M., Schmerk, C. L., Moradizadeh, M., Parvathy, S. N., Figueredo, R., Burton, J. P., Silverman, M. S., Fernandes, R., Maleki Vareki, S., & Haeryfar, S. M. M. (2023). Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 72(5), 1247-1260. https://doi.org/10.1007/s00262-022-03329-8

Vancouver

Ninkov M, Schmerk CL, Moradizadeh M, Parvathy SN, Figueredo R, Burton JP, et al. Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 2023;72(5):1247-1260. doi:10.1007/s00262-022-03329-8

BibTeX
@article{Ninkov2023,
  author = {Ninkov, Marina and Schmerk, Crystal L and Moradizadeh, Manoosh and Parvathy, Seema N and Figueredo, Rene and Burton, Jeremy P and Silverman, Michael S and Fernandes, Ricardo and Maleki Vareki, Saman and Haeryfar, S M Mansour},
  title = {Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {5},
  pages = {1247--1260},
  doi = {10.1007/s00262-022-03329-8}
}
Kostenlos starten →